KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

Abstract

About

This paper, published in 1950, received 655 indexed citations. Written by Maria Dêbiec‐Rychter, Raf Sciot, Axel Le Cesne, M. Schlemmer, Peter Hohenberger, Allan T. van Oosterom, Jean‐Yves Blay, Serge Leyvraz, Michel Stul and Paolo G. Casali covering the research area of Gastroenterology, Pulmonary and Respiratory Medicine and Surgery. It is primarily cited by scholars working on Gastroenterology (585 citations), Pulmonary and Respiratory Medicine (533 citations) and Surgery (271 citations). Published in European Journal of Cancer.

In The Last Decade

doi.org/10.1016/j.ejca.2006.01.030 →

Countries where authors are citing KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

Since Specialization

Citations

This map shows the geographic impact of KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours more than expected).

Fields of papers citing KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

This paper is also available at doi.org/10.1016/j.ejca.2006.01.030.

Explore hit-papers with similar magnitude of impact

Breakdown of academic impact, for the paper White Matter Development During Childhood and Adolescence: A Cross-sectional Diffusion Tensor Imaging Study Breakdown of academic impact, for the paper Learning of Visuomotor Transformations for Vectorial Planning of Reaching Trajectories Breakdown of academic impact, for the paper MUTUAL INFORMATION RELEVANCE NETWORKS: FUNCTIONAL GENOMIC CLUSTERING USING PAIRWISE ENTROPY MEASUREMENTS Breakdown of academic impact, for the paper ThermoTRP channels and beyond: mechanisms of temperature sensation Breakdown of academic impact, for the paper Querying Heterogeneous Information Sources Using Source Descriptions Breakdown of academic impact, for the paper The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis Breakdown of academic impact, for the paper Prestimulus Oscillatory Activity in the Alpha Band Predicts Visual Discrimination Ability Breakdown of academic impact, for the paper Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1)